Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
about
Guideline of Chronic Urticaria BeyondAdvances in Understanding and Managing Chronic UrticariaChronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapyQuestions and answers in chronic urticaria: where do we stand and where do we go?Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticariaHeat urticaria: a revision of published cases with an update on classification and management.Systematic review of treatments for chronic spontaneous urticaria with inadequate response to licensed first-line treatments.Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care.Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms.An overview of the effects of anti-IgE therapies.Omalizumab may not inhibit mast cell and basophil activation in vitro.Chronic urticaria: new management options.Treatment of severely recalcitrant chronic spontaneous urticaria: a discussion of relevant issues.Omalizumab for the treatment of chronic urticaria.EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders.Chronic spontaneous urticaria - a management pathway for patients with chronic spontaneous urticaria.Role of biologics in intractable urticaria.Current challenges and controversies in the management of chronic spontaneous urticaria.Serological evidence that activation of ubiquitous human herpesvirus-6 (HHV-6) plays a role in chronic idiopathic/spontaneous urticaria (CIU).Long-term management of chronic spontaneous urticaria with omalizumab.Current and future therapies for treating chronic spontaneous urticaria.Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature.Looking forward to new targeted treatments for chronic spontaneous urticaria.Controversies and challenges in the management of chronic urticaria.Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.How to manage chronic urticaria 'beyond' guidelines: a practical algorithm.Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.Cholinergic urticaria patients of different age groups have distinct features.Advances in anti-IgE therapyManagement of chronic spontaneous urticaria in the elderly.Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells.Possible therapeutic role of IgE blockade in irritable bowel syndrome.Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis of two cases.Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature.Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria.Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data.The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.Does omalizumab modify a course of recalcitrant chronic spontaneous urticaria?: A retrospective study in Asian patients.
P2860
Q26743369-9E7725B8-99E3-48EE-87C5-C07D832E6289Q26767461-55186DE2-FD1A-4C30-9A41-5042A14EB481Q26777088-B177D487-FA54-478B-AECD-E6ADFA936237Q30249703-866406C6-FC3E-4AC4-BA2A-90191EF9FC2FQ30277818-42D8C109-7153-4DED-BA74-732775606548Q33166940-F8CDC817-D876-4045-8F81-5A1378D4A0EBQ34454209-09CA4478-4FBD-4574-BB0A-19B599297383Q35865960-8982104D-8391-44B2-951A-684D953C5887Q37056739-B8308482-36DC-49CC-85F1-5CD45476CA5CQ37623049-1DC139F4-6B45-426E-8B34-59FD0ED84F28Q38252958-1F51E32D-BCF2-47FE-A398-D250501B10B0Q38254504-1D7167B1-30F2-45BB-B554-39B9D0A60FA1Q38266463-5F4091F4-2EBA-4BFC-9D1E-D1157D2DAC5EQ38276193-2F75ECEA-422B-4D38-8BB6-442E02FBB466Q38310407-7D4ABE67-A0C1-47CC-9FE8-BEC26766F47FQ38394577-A6D22B42-1708-41AF-82BD-CAD05AC82352Q38445637-17D1828E-3A0B-4FE3-9E33-FB85F3815336Q38450662-F6488B64-58AD-430B-AC1D-A8A5A9B06589Q38547047-0F48373B-6016-48F6-81B6-08EC3641F3EFQ38585084-EBE0103E-A9A6-4FC2-BD43-DF766C65CF39Q38709401-A7C60E39-EE8E-429C-95E6-4FFB89C9D3B0Q38751342-69BD2A2A-4C1E-4C1B-AA1B-04BE55E8DE7CQ38754492-7E60B952-82EE-4449-AB4D-3DC5A5ADF4E5Q38771632-4FD4C26E-B8F4-4FC5-926A-ED058B810655Q38861327-C7ACCE9E-F041-40E1-991C-CB243D5F3280Q38861332-A74D6BBE-F29F-418B-A6BA-BAFBD266C98FQ39012896-ED0EB3F7-D0F8-4F39-A690-FDBA92343313Q39269041-17FBCA55-7829-494B-9162-F43FAAAE843DQ39624099-235C9F3D-6DF7-4431-BFAC-2BB6253F9B85Q40057336-06853016-8F9C-4518-81B4-69BF16F137AAQ40812061-4F5612B9-C923-4DA9-B40E-CF7A2B6D8E37Q41103892-4251F356-5DC7-42F2-A226-92FEDE01B416Q41482365-CB6F324A-6495-4860-9BD9-40D48FFDBBC7Q42365599-350BDBDE-2066-4D29-B1D9-BCD156A59925Q42976598-A1F1613B-B887-4B64-9009-210005C27ADEQ43470423-C8CEE7CD-7521-47A5-A123-6FB0B1F0F7EAQ45073951-626B8A58-1E9C-41CD-A01C-D2726F795E18Q47731684-C2681083-023D-4444-A1B9-529D2B911DDBQ48104058-97B6AA60-B0C5-4E7F-A543-85A4A7062793Q48169089-13A9E725-228D-45C9-B564-5C389110B8CF
P2860
Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Omalizumab is an effective and ...... trospective clinical analysis.
@en
Omalizumab is an effective and ...... trospective clinical analysis.
@nl
type
label
Omalizumab is an effective and ...... trospective clinical analysis.
@en
Omalizumab is an effective and ...... trospective clinical analysis.
@nl
prefLabel
Omalizumab is an effective and ...... trospective clinical analysis.
@en
Omalizumab is an effective and ...... trospective clinical analysis.
@nl
P2093
P1476
Omalizumab is an effective and ...... trospective clinical analysis.
@en
P2093
Marcus Maurer
Martin K Church
Tatevik Ohanyan
P356
10.1016/J.JDERMSCI.2013.08.011
P50
P577
2013-09-03T00:00:00Z